文献速递湿疹皮炎与荨麻疹

奥马珠单抗治疗慢性自发性荨麻疹的有效性:基于患者报告结局的前瞻性研究

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-05-29

这项为期6个月的前瞻性试验在皮肤科大学科室纳入117例抗组胺药难治的慢性自发性荨麻疹患者,每4周给予奥马珠单抗300 mg。3个月时UAS7从基线29.3分降至11.9分,差异17.4分(95%CI 14.8-19.9,P<0.0001),3至6个月间无进一步显著改善;既往使用传统免疫抑制剂与3个月时较差的治疗反应相关(P<0.001)。

要点

  • 奥马珠单抗300 mg每4周治疗抗组胺药难治CSU,3个月时UAS7较基线降低17.4分(95%CI 14.8-19.9,P<0.0001)。
  • 3至6个月随访间患者报告结局无进一步显著改善。
  • 既往使用硫唑嘌呤、环孢素或甲氨蝶呤与3个月时较差的治疗反应相关(P<0.001)。

核心结论

  • 奥马珠单抗是抗组胺药难治性慢性自发性荨麻疹的高效疗法,其治疗效果与随机对照试验中观察到的相似。
  • 经过验证的患者报告结局用于评估疾病活动度、疾病控制和生活质量受损,是CSU临床管理中有价值的工具。
  • 仍需要识别CSU中奥马珠单抗疗效和安全性的患者特异性预测因素。

研究设计与样本

  • 为期6个月的前瞻性试验,在皮肤科大学科室纳入抗组胺药难治的慢性自发性荨麻疹患者,给予奥马珠单抗300 mg每4周一次。
  • 共纳入117例患者(39例男性、78例女性),平均年龄42岁。
  • 主要结局为3个月时过去一周荨麻疹活动度评分(UAS7)。

主要发现

  • 基线UAS7平均为29.3分(SD=10.8),3个月随访时改善至11.9分(SD=12.9),差异=17.4分(95%CI:14.8-19.9),P<0.0001。
  • 其他患者报告结局在3个月治疗期间也显著改善。
  • 3个月至6个月随访之间未见进一步显著改善。
  • 性别、年龄、CSU发病年龄、症状持续时间、是否合并慢性诱导性荨麻疹(CINDU)、合并症、荨麻疹HR试验阳性、吸烟、种族、血管性水肿、血清总IgE水平、CRP、白细胞、中性粒细胞绝对计数或既往使用泼尼松龙或孟鲁司特治疗,均与3个月时奥马珠单抗治疗反应无显著关联,所有比较P>0.05。
  • 既往使用传统免疫抑制剂(硫唑嘌呤、环孢素或甲氨蝶呤)与3个月时较差的治疗反应相关,P<0.001。

临床怎么用

  • 奥马珠单抗300 mg每4周一次可用于抗组胺药难治的慢性自发性荨麻疹,3个月时UAS7较基线降低17.4分(95%CI 14.8-19.9,P<0.0001)。
  • 经过验证的患者报告结局可用于评估CSU疾病活动度、疾病控制和生活质量受损。

局限性

  • 仍需要识别CSU中奥马珠单抗疗效和安全性的患者特异性预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To examine the effectiveness of omalizumab (anti-IgE) on symptoms and disease-related quality of life in chronic spontaneous urticaria (CSU) and to identify possible patient-specific factors associated with response to omalizumab in patients with antihistamine refractory CSU. METHODS: Six months prospective trial of omalizumab 300 mg every 4 weeks among patients with CSU from a dermatological university department. The primary outcome was the urticaria activity score in the past week (UAS7) at 3 months. RESULTS: A total of 117 patients (39 men and 78 women) with a mean age of 42 years were included. The mean baseline UAS7 score was 29.3 points (SD = 10.8), which improved to 11.9 points (SD = 12.9) at 3 months follow-up, difference = 17.4 points (95% CI: 14.8-19.9), P < 0.0001. Other patient-reported outcomes (PROs) also improved significantly during 3 months of treatment. No significant further improvement was seen between three and 6 months follow-up. None of the following patient-specific factors: sex, age, age of onset of CSU, symptom duration, presence of chronic inducible urticaria (CINDU), comorbidities, positive urticaria HR test, smoking, ethnicity, angio-oedema, serum total IgE level, CRP, leucocytes, absolute neutrophil count or previous treatment with prednisolone or montelukast were significantly associated with response to omalizumab at 3 months, P > 0.05 for all comparisons. Previous treatment with traditional immunosuppressant drugs (azathioprine, cyclosporine or methotrexate) was associated with poorer treatment response to omalizumab at 3 months, P < 0.001. A strong correlation was seen between different patient-reported outcomes (PROs) at baseline and 3 months follow-up. Fifteen patients (12.8%) reported side-effects of the treatment. CONCLUSION: Omalizumab is a highly effective therapy for antihistamine refractory CSU with treatment effects similar to those observed in randomized controlled trials. Validated PROs to assess disease activity, disease control and impairment of quality of life are valuable tools in the clinical management of CSU. Identification of patient-specific predictors of effect and safety of omalizumab in CSU is still warranted.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Ghazanfar MN, Holm JG, Thomsen SF, et al. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. J Eur Acad Dermatol Venereol. 2018. PMID: 29729103. doi:10.1111/jdv.15045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。